Related Experiment Video

Updated: May 24, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines

Norio Kondo1, Mamoru Tsukuda, Atsuko Sakakibara

  • 1Department of Otorhinolaryngology, Tama-Hokubu Medical Center, Tokyo, Japan. norio_kondo@tahamoku-hp.jp

International Journal of Oncology
|February 21, 2012
PubMed

Insights

Combining cetuximab and trastuzumab shows significant antiproliferative effects against head and neck squamous cell carcinoma (HNSCC) by targeting epidermal growth factor receptor (EGFR) and HER-2. While antibody-dependent cell-mediated cytotoxicity (ADCC) was observed, a synergistic effect was not evident.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Epidermal growth factor receptor (EGFR) and HER-2 are frequently co-overexpressed in various cancers, potentially driving tumor growth.
  • Head and neck squamous cell carcinoma (HNSCC) presents a significant clinical challenge, with opportunities for targeted therapies.

Purpose of the Study:

  • To investigate the combined antitumor effects of cetuximab and trastuzumab on HNSCC.
  • To evaluate the antiproliferative activity and antibody-dependent cell-mediated cytotoxicity (ADCC) of this combination therapy.

Main Methods:

  • Utilized 16 HNSCC cell lines to assess mRNA expression of EGFR, HER-2, HER-3, and HER-4.
  • Conducted in vitro proliferation assays to determine cell viability under combination treatment.
  • Evaluated ADCC using peripheral blood mononuclear cells (PBMCs) and analyzed HER-2 gene status for mutations.

Main Results:

  • Combination treatment of cetuximab and trastuzumab significantly reduced HNSCC cell viability compared to monotherapy.
  • No correlation was found between EGFR, HER-2, HER-3, or HER-4 mRNA expression levels and the efficacy of the combination treatment.
  • Individual drugs induced ADCC, but a significant synergistic effect of the combination on ADCC was not observed. No HER-2 mutations were detected.

Conclusions:

  • Combined targeted therapy with cetuximab and trastuzumab demonstrates significant antiproliferative potential in HNSCC.
  • The efficacy of this combination is not directly correlated with the expression levels of EGFR, HER-2, HER-3, or HER-4.
  • Further investigation is warranted to optimize combination strategies for HNSCC treatment.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...